
Absci reports positive data from Phase I alopecia trial
Biopharmaceutical company Absci has reported positive data from the Phase I trial of its alopecia treatment. ABS-201, an investigational anti-prolactin receptor (PRLR) antibody, was evaluated in a first-in-human, randomised, double-blind, placebo-controlled study in 32 healthy volunteers with and without androgenetic alopecia (AGA). The medication proved to be well-tolerated across… Read More







